Company Description
Gelteq is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products.
A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product.
Our principal products are edible gels and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers.
We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license.
Of our products already licensed, two clients have placed initial orders for nutraceutical products, and there have been four other products in the sports vertical ordered.
With regards to the pets, nutraceutical and sports vertical, we designed these products to have no regulatory hurdles to overcome as they have food grade classifications and therefore do not require regulatory approvals.
We designed our gel platform to enhance the tolerability and stability of drugs while maintaining their efficacy.
Products in the pharma vertical will require regulatory approval.
| Country | Australia |
| Founded | 2018 |
| Industry | Health Care |
| Sector | Pharmaceuticals |
| Employees | 5 |
| CEO | Nathan J. Givoni |
Contact Details
Address: Level 4, 100 Albert Road South Melbourne, VIC 3025 Australia | |
| Phone | +61 3 9087 3990 |
| Website | gelteq.com |
Stock Details
| Ticker Symbol | GELS |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001920092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Simon H. Szewach | Executive Chairman (Board Member) |
| Nathan J. Givoni | Chief Executive Officer and Director (Board Member) |
| Neale A. Java | Chief Financial Officer |
| Jeffrey W. Olyniec | Independent Director (Board Member) |
| Dr. Paul M. Wynne | Independent Director (Board Member) |
| Hon. Philip A. Dalidakis | Independent Director (Board Member) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | EFFECT | Notice of Effectiveness |
| Feb 29, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 5, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 15, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 3, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Mar 29, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Mar 17, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Feb 6, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 9, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 30, 2022 | F-1 | Registration statement for certain foreign private issuers |